



MSD Pipeline

Q4 2024 Reflecting Pipeline to
Nov 1, 2024

Lead-in language

The chart below reflects the company's research pipeline as of **Nov 1, 2024**. Candidates shown in Phase 3 include specific products and the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer and certain other indications) and additional claims, line extensions or formulations for in-line products are not shown.

MSD pipeline as of Nov 1, 2024

1. Being developed in a collaboration.
2. Being developed in combination with Keytruda
3. Being developed as monotherapy and/or in combination with Keytruda

▶ Moved forward since last pipeline update.

Phase 2	Phase 2	Phase 2	Phase 2	Phase 2
▶ Cancer Bladder Cervical Endometrial Esophageal Gastric HNSCC Melanoma Ovarian Pancreas Prostate patritumab deruxtecan MK-1022 ¹	Cancer NSCLC quavonlimab MK-1308 ²	Cancer CRC quavonlimab + pembrolizumab MK-1308A	Thrombosis MK-2060	▶ Cancer Biliary Bladder Breast Cervical CRC Endometrial Esophageal HNSCC Ovarian ifinatamab deruxtecan MK-2400 ¹
Cancer Biliary CRC Neoplasm Malignant Pancreatic sacituzumab tirumotecan MK-2870 ^{1,3}	Cancer Advanced solid tumors Prostate KEYTRUDA [®] MK-3475	▶ Cancer Cutaneous Squamous Cell Heme pembrolizumab + hyaluronidase subcutaneous MK-3475A	Cancer NSCLC favezelimab MK-4280 ²	Cancer Bladder CRC Cutaneous Squamous Cell Endometrial Esophageal Melanoma RCC favezelimab + pembrolizumab MK-4280A
PH-COPD MK-5475	Cancer Neoplasm Malignant boserolimab MK-5890 ²	Cancer Ovarian raludotatug deruxtecan MK-5909 ¹	NASH efinopegdutide MK-6024	Vitiligo MK-6194

MSD pipeline as of Nov 1, 2024

1. Being developed in a collaboration.
2. Being developed in combination with Keytruda
3. Being developed as monotherapy and/or in combination with Keytruda
4. On FDA clinical hold

▶ Moved forward since last pipeline update.

Phase 2	Phase 2	Phase 2	Phase 2	Phase 2
Cancer Endometrial Esophageal HCC Prostate Rare cancers WELIREG™ MK-6482³	Cancer Advanced solid tumors LYNPARZA® MK-7339^{1,3}	Cancer Bladder CRC Endometrial Melanoma Ovarian Prostate RCC vibostolimab + pembrolizumab MK-7684A	Pulmonary Hypertension due to Left Heart Disease WINREVAIR™ MK-7962	HIV-1 PrEP MK-8527
HIV-1 Infection islatravir+MK-8507 MK-8591B⁴	Dengue fever virus Vaccine V181	Cancer Bladder Cutaneous Squamous Cell Carcinoma RCC V940^{1,2}		

MSD pipeline as of Nov 1, 2024

1. Being developed in a collaboration.
2. Being developed in combination with Keytruda
3. Being developed as monotherapy and/or in combination with Keytruda
4. On partial clinical hold for higher doses than those used in current clinical trials
5. Available in the U.S. under Emergency Use Authorization
6. Program is in a Phase 2/3 study

▶ Moved forward since last pipeline update.

Phase 3	Phase 3	Phase 3	Phase 3	Phase 3
Hypercholesterolemia enlicitide decanoate MK-0616	Cancer NSCLC patritumab deruxtecan MK-1022¹ (EU)	Cancer Heme nemtabrutinib MK-1026	Cancer NSCLC MK-1084²	Cancer RCC quavonlimab + pembrolizumab MK-1308A
Respiratory syncytial virus clesrovimab MK-1654	▶ Cancer Heme zilovertamab vedotin MK-2140	Cancer SCLC ifinatumab deruxtecan MK-2400¹	Cancer Breast Cervical Endometrial Gastric NSCLC sacituzumab tirumotecan MK-2870^{1,3}	▶ Diabetic macular edema Restoret™ MK-3000⁶
Cancer Hepatocellular (EU) Ovarian SCLC KEYTRUDA® MK-3475	Cancer NSCLC pembrolizumab + hyaluronidase subcutaneous MK-3475A	Cancer Myeloproliferative Disorders bomedemstat MK-3543	Cancer Heme favezelimab + pembrolizumab MK-4280A	Anti-Viral COVID-19 LAGEVRIO® MK-4482^{1,5} (US)
Cancer Prostate opevesostat MK-5684¹	Ulcerative Colitis tulisokibart MK-7240	Cancer NSCLC SCLC LYNPARZA® MK-7339^{1,2}	Cancer NSCLC vibostolimab + pembrolizumab MK-7684A	Cancer Esophageal Gastric LENVIMA® MK-7902^{1,2}
HIV-1 infection doravirine + islatravir MK-8591A⁴	▶ HIV-1 Infection islatravir + lenacapavir MK-8591D^{1,4}	Cancer Melanoma NSCLC V940^{1,2}		

MSD pipeline as of Nov 1, 2024

1. Being developed in a collaboration
2. In June 2024, FDA issued a CRL for the BLA for patritumab deruxtecan. MSD is working with Daiichi Sankyo to address FDA feedback.

▶ Moved forward since last pipeline update.

New Molecular Entities Under Review	New Molecular Entities Under Review	Certain Supplemental Filings Under Review	Certain Supplemental Filings Under Review	Certain Supplemental Filings Under Review
<p>Previously Treated Locally Advanced or Metastatic EGFR-Mutated NSCLC (HERTHENA-Lung01) patritumab deruxtecan MK-1022^{1,2} (US)</p>	<p>von Hippel-Lindau (VHL) disease (LITESPARK-004) Previously Treated Advanced Renal Cell Carcinoma (LITESPARK-005) WELIREG® MK-6482 (EU, JPN)</p>	<p>High-Risk Locally Advanced Cervical Cancer (KNA18) KEYTRUDA® MK-3475 (JPN)</p>	<p>Primary Advanced or Recurrent Endometrial Carcinoma (KN868) KEYTRUDA® MK-3475 (JPN)</p>	<p>1L Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (KN483) KEYTRUDA® MK-3475 (EU, JPN)</p>
<p>Pneumococcal Vaccine Adult CAPVAXIVE™ V116 (EU, JPN)</p>				

1. Approvals obtained within the last 3 months.

▶ Moved forward since last pipeline update.

MSD pipeline as of Nov 1, 2024

New Molecular Entities Approvals ¹	Certain Supplemental Approvals ¹	Certain Supplemental Approvals ¹	Certain Supplemental Approvals ¹
▶ Pulmonary Arterial Hypertension (STELLAR) WINREVAIR™ MK-7962 (EU)	▶ 1L Melanoma (LEAP-003 / KN151) KEYTRUDA® MK-3475 (CHN)	▶ High-Risk Locally Advanced Cervical Cancer (KNA18) KEYTRUDA® MK-3475 (EU)	▶ 1L Locally Advanced or Metastatic Urothelial Cancer (KNA39) KEYTRUDA® MK-3475 (EU, JPN)
	▶ 1L Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (KN483) KEYTRUDA® MK-3475 (US)	▶ Resectable Stage II, IIIA or IIIB NSCLC (KN671) KEYTRUDA® MK-3475 (JPN)	▶ Primary Advanced or Recurrent Endometrial Carcinoma (KN868) KEYTRUDA® MK-3475 (EU)

Forward-looking statement

This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No duty to update

The information contained in the presentation set forth below was current as of Nov 1, 2024. While this presentation remains on the company's website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after Nov 1, 2024.

The chart reflects the MSD research pipeline as of Nov 1, 2024.

Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not shown.